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Biologically active, therapeutically useful, DNA binding
natural products continue to reveal new paradigms for
sequence-selective recognition, to enlist beautiful
mechanisms of in situ activation for DNA modifica-
tion, to define new therapeutic targets, to exploit new
mechanisms to achieve cellular selectivity, and to
provide a rich source of new drugs. These attributes
arise in compact structures of complex integrated
function.
Introduction
DNA-interacting small molecules are of exceptional im-
portance in medicine, accounting for a significant por-
tion of all anticancer drugs [1, 2]. Over 60% of the clin-
ical anticancer drugs introduced through 2002 are
natural products or natural product derivatives, and
most exert their effects by acting on DNA [1, 2]. Since
the clinical introduction of mustards in the 1940s and
Sidney Farber’s use of the natural product actinomycin
D (1954), when the mechanism of actions were un-
known, much progress has been made toward under-
standing small molecule-DNA recognition. It was the
landmark elucidation of the DNA structure by Watson
and Crick that allowed the seminal conceptualization of
DNA intercalation by Lerman in 1961 [3] and the eluci-
dation of the origin of actinomycin’s properties [4, 5].
In the subsequent 40 years, extensive studies have de-
fined a number of small molecule DNA binding modes
and recognition paradigms [6]. Most have arisen as a
consequence of defining the site of action (DNA) of bio-
logically active natural products and the subsequent
elucidation of their binding selectivity and bound struc-
ture. Although general patterns of recognition are now
appreciated, subtle structural features important to the
DNA binding affinity or selectivity and the ensuing ef-
fects are still being unraveled. The advances may be
attributed in part to the continued introduction of increas-
ingly powerful new tools (e.g., footprinting, chemical
synthesis, computational tools, gene profiling) as well
as improvements in methods used for nucleic acid
structure determination (e.g., X-ray, NMR).
The cumulative understanding of ligand-DNA re-
cognition and the availability of such tools have pro-
vided the foundation for the design targeting of DNA
and RNA in drug discovery, a strategy intuitively ap-
pealing in this postgenomic era. Most promising are the
advances in the design of sequence-specific DNA bind-
ing compounds for the inhibition of transcription. Such*Correspondence: boger@scripps.eduefforts have been recently reviewed [7–11]. In spite of
the advances, the de novo design of sequence-selec-
tive DNA binding agents is not yet straightforward, and
the derivation of therapeutic compounds (e.g., antitu-
mor drugs) remains an even more complex task. It is of
special note that the most successful de novo ap-
proach to date entails the systematic elaboration of the
hairpin polyamides that emerged from the examination
of the natural product distamycin. In a large measure,
this difficulty in de novo design may be attributed to
the constellation of properties that must be embodied in
a single structure to provide a biologically active, thera-
peutically useful, sequence-selective DNA binding
agent. It is in this regard that natural products continue
to be especially valuable. In addition to providing new
paradigms for sequence-selective recognition and beau-
tiful mechanisms of activation for DNA modification, new
therapeutic targets have been defined (e.g., topoisomer-
ase inhibition [12–16]), unanticipated sources of cellular
selectivity discovered, and a series of important drugs
introduced. The latter attributes were selected by
screening, and even today many such lessons on integ-
rated function within natural products remain unrecog-
nized.
What is not addressed herein but is of equal impor-
tance is the central role that such natural products have
and will continue to play in driving technological ad-
vances in chemistry and biology. Complementing the
advances in biology that emerge from their study, the
rich histories surrounding each natural product’s identi-
fication and isolation, the remarkable science leading
to their structure determination, and the beautiful semi-
synthetic and the landmark total synthesis studies used
for structure confirmation, material access, and sophis-
ticated SAR investigations have been conducted on
structures so complex that they push the frontiers of
the science, spawning countless advances for the field
of organic synthesis and chemistry (for a detailed cov-
erage of the historical importance that natural products
played in the discovery of biologically active DNA bind-
ing compounds and the impact this had on chemistry,
see reference [17]). This may be a direct consequence
of the complex integrated function assembled in the
compact structure of naturally occurring DNA binding
compounds required to provide the rich constellation
of chemical, physical, and functional properties.
Modes of DNA Binding
Intercalation
For small molecules that associate with DNA, three
modes of binding are used to classify the interaction:
intercalation, minor groove binding, and major groove
binding [6]. The concept of intercalation was first rec-
ognized in studies on the aminoacridines by Lerman
[3]. The proposal resulted from the observation of phys-
ical changes in DNA upon binding proflavin, including
changes in DNA X-ray diffraction patterns, an increase
in viscosity, and the lowering of the sedimentation coef-
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hallmark of intercalation, of which the extension of the [
double helix and its local unwinding at the site of bind-
ing are most prominent. The connection between inter- m
calation and the structural nature of the DNA distortion t
provided the basis for the correlation between simple y
intercalation (misrecognized as a base pair) and muta- a
genic potential and brought to preeminence DNA- t
targeted chemotherapy [18, 19]. a
An extensive range of natural products bind to DNA [
with intercalation [20, 21] (Table 1, Intercalation; Figure e
1A), and most make additional groove contacts contrib- n
uting to their sequence preference. A number of the p
natural products categorized herein as minor or major
groove binders are further stabilized by intercalation of M
a pendant chromophore or quinone. In fact, an impor- G
tant de novo design application of intercalators is their t
analogous attachment to sequence-selective groove s
binding molecules to enhance their affinity, selectivity, m
or temporal stability. d
The structural features that drive intercalation and F
the selectivity of binding, although appearing fairly sim- g
ple, are complex and have been the subject of exten- c
sive study [6, 20, 21, 66]. The major driving forces are s
thought to be π-stacking and stabilizing electrostatic s
interactions, where the chromophore seeks maximum w
overlap with the flanking DNA base pairs (parallel inter- o
calation). A typical example is provided by the tricyclic r
heterocycle of actinomycin positioned within DNA to
make maximal base pair (bp) overlap such that the cy- s
clic peptide substituents reside in the minor groove
d
[67]. However, a number of perpendicular intercalators
a
(e.g., anthracyclines) are known that thread end to end
v
through DNA from the minor to major groove. From
t
these studies, a generalized preference has emerged
t
for intercalation to occur preferentially at an alternating
cpyrimidine-purine site, perhaps with a weak selectivity
ffor 5#-CG versus 5#-TA. Offsetting the stabilizing π-stack-
Cing and electrostatic interactions is a distortion of the
thelix and disruption of existing bp-stacking interac-
ctions. Simplistically, it is now thought that the inherent
d
π-stacking stabilization at a pyrimidine-purine (Py-Pu)
gsite is weaker and easier to disrupt than that of a pu-
Drine-purine (pyrimidine-pyrimidine) site [6].
iA second, fundamental concept that emerged from
the examination of naturally occurring DNA binding
mmolecules is bisintercalation. A now classic series of
anatural products have been identified since the seminal
tstudies on echinomycin [34] and triostin A [68, 69] that
ihave been shown to bind by bisintercalation spanning
ta 2 bp site. Of these, the binding of sandramycin (Figure
a2) is perhaps the most straightforward to appreciate
f[37, 38, 70]. It embodies three fundamental features
pthat dictate preferential binding at a 5#-CATG site: (1)
ubisintercalation of the pendant chromophores spanning
a2 bp, (2) binding of the linking cyclic depsipeptide in
sthe more accessible deeper, AT-rich minor groove span-
Bning the intercalation sites, and (3) preferential interca-
tlation at two 5#-PyPu sites. However, nature’s design
tis far from simple, requiring adoption of a disfavored
msandramycin conformation bearing two cis amides in
torder to span 2 versus 3 bp and binding stabilization
fthat is derived principally from the depsipeptide minor
agroove contacts that drive rather than follow from thesequential intercalations that provide a temporal sta-ility to the complex which defies intuition (t1/2 = 10 hr)
37, 38].
Following the very early clinical success with actino-
ycin D [71], arguably many of the most important anti-
umor drugs introduced into the clinic over the last 30
ears have emerged from this class, including the
nthracyclines (e.g., daunorubicin, doxorubicin) [23],
he camptothecins (e.g., topotecan, irinotecan) [72, 73],
nd the podophyllotoxins (e.g., teniposide, etoposide)
30]. Studies surrounding the former defined DNA as an
ffective site of action [4, 5], and the latter two defined
ew and now classic therapeutic targets (trap of the to-
oisomerase I or II cleavable complex with DNA [14, 15]).
inor Groove Binding
roove binding small molecules are more recent addi-
ions to the field [6]. Although not yet heavily repre-
ented with drugs in clinical use, minor groove binding
olecules are thought to hold the most promise for
e novo design [6–11] (Table 1, Minor Groove Binding;
igure 1B). Interactions with individual bp along the
roove floor and the deoxyribose groove walls provide
ooperative binding contacts, extended recognition
pecificity, and the potential for a high degree of target
electivity. Binding affinity, originally thought to be
eak, now has demonstrated affinities exceeding that
f the classical intercalators and approaching that of
egulatory proteins [10].
The structural features found to be most critical to
mall molecule recognition are groove width, groove
epth, floor functionality, and electrostatic potential,
nd are all sequence dependent. Minor groove widths
ary from 3–4 Å for AT-rich tracts to over 8 Å for GC
racts. Groove depth is more shallow for GC sequences
han for AT tracts due to the presence of the G exocy-
lic C2-amine. A compensating feature of this groove
loor functionality is the nucleophilic character of the G
2-amine (an alkylation site) and the additional oppor-
unity it provides for recognition through H bonding. In
ontrast to intercalation, where compound binding in-
uces a large change in DNA conformation, minor
roove binding is characterized by little or no apparent
NA distortion and often occurs with induced changes
n the bound compound conformation.
Distamycin and netropsin exemplify a large class of
inor groove binding molecules better known for their
ntiviral than anticancer properties. They are charac-
erized by repeating pyrrole subunits connected by am-
de bonds and usually terminate with one or more posi-
ively charged (protonated) nitrogen atoms. They were
mong the first compounds that displayed selectivity
or AT sequences, and it is their characterization that
rovided the foundation for much of what we now
nderstand about minor groove binding selectivity and
ffinity [8, 10, 11, 74]. The molecules possess a curved
hape that can closely match the helical pitch of the
-DNA minor groove. The origin of their binding selec-
ivity, often referred to as “shape-selective binding,” en-
ails preferential binding in the narrower, deeper AT-rich
inor groove, where the stabilizing van der Waals con-
acts are optimized [59]. Further stabilizing the complex
ormation are accommodated H bonds of the linking
mides with the floor bps and stabilizing electrostaticinteractions of the terminal protonated amines [59].
Review
1609Table 1. Representative Anticancer Natural Products that Interact with DNA by Intercalation, Minor Groove, and Major Groove Binding
Intercalation
Binding Compound Selectivity Action Activation Reference
Daunomycina 5#-WCG inhibition of topoisomerase II none (reductive?) [22]
Doxorubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [4, 5, 14]
Aclarubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [23]
Idarubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [23]
Epirubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [23]
Pirarubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [24]
Valrubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [23]
Amrubicina 5#-WCG inhibition of topoisomerase II none (reductive?) [23]
Nogalamycin 5#-TG, 5#-GT unknown none [25]
Actinomycin Da 5#-PyGCPu inhibition of topoisomerase II none [4, 5]
Camptothecin ND inhibition of topoisomerase I none [26, 27]
Topotecana ND inhibition of topoisomerase I none [12]
Irinotecana ND inhibition of topoisomerase I none [12]
Rebeccamycin ND inhibition of topoisomerase I none [28]
Ellipticine GC-rich inhibition of topoisomerase II none (oxidative?) [29]
Podophyllotoxin ND inhibition of topoisomerase II (?) none [30]
Etoposidea ND inhibition of topoisomerase II none [30, 31]
Teniposidea ND inhibition of topoisomerase II none [30]
Elsamicin 5#-PuG inhibition of topoisomerase II none [32]
Dynemicin 5#-PuPy ds DNA cleavage reductive [33]
Echinomycin 5#-CG bisintercalation none [34]
Triostin A 5#-CG bisintercalation none [35]
Luzopeptins 5#-CATG bisintercalation none [36]
Sandramycin 5#-CATG bisintercalation none [37, 38]
Quinoxapeptin 5#-AT, 5#-TA bisintercalation none [36]
Thiocoraline none bisintercalation none [39]
Mitoxantronec 5#-PuPy inhibition of topoisomerase II none [40]
Bisantrenec 5#-PuPy inhibition of topoisomerase II none [41]
m-AMSAc 5#-PuPy inhibition of topoisomerase II none (oxidative?) [42]
Minor Groove Binding
Bleomycina 5#-GC, 5#-GT ds DNA cleavage oxidative (Fe+2 chelation) [43]
Mitomycin Ca 5#-CG alkylation/crosslinking reductive [44]
FR66979 5#-CG alkylation/crosslinking reductive [45, 46]
Mithramycina G-rich RNA synthesis inhibition none (Mg+2 chelation) [47]
Duocarmycins 5#-WWWA alkylation target selective [48, 49]
CC-1065 5#-WWWWA alkylation target selective [48, 49]
Yatakemycin 5#-WWAWW alkylation target selective [50]
Neocarzinostatin 5#-GT DNA cleavage nucleophilic [51]
Calicheamicinsb 5#-TPyPyT ds DNA cleavage nucleophilic [52]
Retrorsine 5#-CG alkylation/crosslinking oxidative [53]
Anthramycins 5#-PuGPu alkylation none [54]
Saframycins 5#-GGS alkylation reductive [55, 56]
Ecteinascidin 743 5#-PuGS alkylation dehydration [57]
Isochrysohermidin 5#-CG reversible crosslinking none [58]
Distamycin A/T-rich RNA synthesis inhibition none [59]
Netropsin A/T-rich RNA synthesis inhibition none [59]
Major Groove Binding
Pluramycins 5#-PyG intercalation/alkylation oxidative [60]
Aflatoxins 5#-GGG intercalation/alkylation oxidative [61]
Azinomycins 5#-GNT, 5#-GNC intercalation (?)/crosslinking none [62]
Leinamycin ND intercalation/alkylation nucleophilic [63, 64]
Ditercalinium 5#-CGCG bisintercalation none [65]
ND, not determined. W = A or T; S = C or G.
a Clinically approved antitumor drug.
b Clinically used as an antibody conjugate.
c Synthetic drug.Despite the extensive studies with distamycin, it was
not until 1989 that the discovery was made that it can
bind in a cooperative 2:1 as well as 1:1 complex with
DNA [75]. The impact of this observation on syntheti-
cally designed agents (hairpin polyamides) has been re-
markable. When this binding mode was recognized, the
expanded groove width requirements could be com-
bined with ongoing design modifications used to ex-tend the binding recognition to a GC bp (incorporate
H-bond acceptor, lexitropsins) to provide linked hairpin
polyamides capable of reading specific DNA sequences.
The subject of distamycin-inspired minor groove binders
has been reviewed elsewhere [8, 10, 11, 74].
The variable conformational shape of the minor groove
not only provides the opportunity for such shape-selec-
tive binding, but also for “shape-dependent catalysis.”
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1610Figure 1. Structures of Selected Antitumor Natural Products that Bind DNA
(A), intercalation; (B), minor groove binding; (C), major groove binding; (D), Watson-Crick base pairing of DNA nucleotides.The duocarmycins are exceptionally potent antitumor t
iagents that derive their properties through a sequence-
selective minor groove alkylation [48]. Not only have shey been shown to exhibit an AT-rich binding selectiv-
ty like that of distamycin (shape-selective binding), but
uperimposed on this binding selectivity is a shape-
Review
1611Figure 2. Two Views of the 5#-d(GCATGC)2-Sandramycin Complex
Two views of the 5#-d(GCATGC)2-sandramycin complex as deter-
mined by NMR, illustrating the symmetrical minor groove binding
of the cyclic decadepsipeptide and the bisintercalation sandwich-
ing the central 2 A-T bp [37].dependent catalysis [49, 76], which also occurs prefer-
entially in the narrower, deeper AT-rich minor groove.
Thus, although the duocarmycins are unreactive toward
conventional nucleophiles at pH 7, the DNA alkylation
is exceptionally facile. This target selective reactivity
is derived from a DNA binding induced conformational
change in the molecule that twists the linking amide,
disrupting the crossconjugated vinylogous amide stabi-
lization of the cyclohexadienone and activating the cy-
clopropane for nucleophilic attack (Figure 3). This
unique target-derived activation requires no chemical
reaction. Rather, the increased reactivity derived from
the binding-induced conformational change in the
compound, which is greatest in the narrower AT-rich mi-
nor groove, is sufficient to accelerate (catalyze) the al-
kylation reaction [48, 49, 76].
An exquisite minor groove binding natural product is
bleomycin [43, 77, 78]. The bulk of its DNA binding af-
finity resides with the C terminus sulfonium salt (major
groove), bithiazole (perpendicular intercalation), and
the linker valerate-threonine subunits (minor groove).
The bithiazole serves as a swivel point for 180° rotation,
permitting association with either strand of DNA from a
single intercalation site (double-strand DNA cleavage),
and each substituent on the linker region contributes
to adoption of a single, rigid, compact conformation
(Figure 4), productive for double-strand (ds) versus sin-
gle-strand (ss) DNA cleavage. The N terminus chromo-
phore chelates metals (Fe+3, Cu+2) and activates O2,
producing a powerful oxidant, and the 4-aminopyrimi-
dine forms key triplex-like H bonds with G at the 5#-GC,
5#-GT cleavage sites, anchoring the metal-bound oxi-
dant proximal to DNA for H-atom abstraction (Figure 4).
Every subunit and nearly every functional group or sub-
stituent within bleomycin contributes to its functional
binding and cleavage of DNA. In addition to its clinical
use as an anticancer drug, bleomycin served as the inspi-
ration and design template for the chemical footprinting
[79] and affinity cleavage [80] tools used today, and it
has emerged as one of nature’s most exquisitely de-
signed natural products of integrated function.Figure 3. Models Illustrating the Alkylation at the Same Site within
Duplex 5#-d(GACTAATTTTT) DNA by (+)-Duocarmycin SA and ent-
(−)-Duocarmycin SA
Upper left, (+)-duocarmycin SA; upper right, ent-(−)-duocarmycin
SA. The binding of the natural enantiomer extends in the 3# to 5#
direction from the adenine-N3 alkylation site across the sequence
5#-CTAA, whereas that of the unnatural enantiomer binds in the re-
verse 5# to 3# direction across the site 5#-AATT [95]. Below, groove
view NMR structure of (+)-duocarmycin SA bound to 5#-GATTA
highlighting the DNA binding-induced intersubunit twist (conforma-
tional change) leading to alkylation catalysis [49].Major Groove Binding
DNA major groove binding has not been exploited with
small molecules or natural products to the same extent
as the minor groove [6]. This is surprising since the ma-
jor groove contains more H-bond donor and acceptor
sites and consequently more information. In fact, the
majority of proteins contact and recognize (read) this
face of DNA. It has been suggested that the wider ma-
jor groove provides a much larger, shallower binding
pocket less effective for small molecule binding than
the narrower, deeper minor groove [6].
To date, there are only a few examples of natural pro-
ducts that bind selectivity in the major groove (Table 1,
Major Groove Binding; Figure 1C). Most such com-
pounds bind by intercalation and make further H-bond
contacts in the major groove. Examples include diter-
calinium and leinamycin, where the major groove inter-
actions provide some degree of sequence specificity,
but the binding affinity is provided principally by the
intercalation event. The vast majority of the major
groove binding natural products further alkylate DNA (G
or A N7) via epoxide or aziridine electrophiles through
Chemistry & Biology
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Figure 4. Expanded View of CoIII-OOH Bleomycin A2 Bound to DNA u
Determined by NMR a
This view illustrates two key H bonds between the pyrimidoblamic
acid subunit (C4 amino group and N3 atom) and the guanine at the E
cleavage site. Also highlighted are the C4#-H abstraction site
t(green), the CoIII-OOH subunit (green ball and violet stick), and the
rigid, compact conformation of the linker domain [106]. For clarity,
the disaccharide subunit is not shown. B
t
fproximity-induced reactivity (affinity-induced reactivity). A c
large measure of this selectivity can be attributed to G
N7 being the most reactive nucleophilic site in DNA M
rather than to inherent noncovalent binding selectivity. T
a
rDNA Modification
Three fundamental features often arise in the study of a
aDNA binding natural products: binding affinity, binding
mode and selectivity, and reaction or effector selectiv- d
fity, including DNA cleavage, alkylation, or crosslinking.
Each can independently assert levels of control on the e
Dsequence-selective recognition of DNA [81], and the
establishment of the relative role of these effects re- m
omains a primary objective of most studies. In fact, most
of what is known today about the chemical modifica- f
vtion of DNA emerged from such studies on natural pro-
ducts. The majority of all reactions can be grouped into p
dtwo categories: (1) reaction of electrophiles with nucleo-
philic sites on DNA or (2) reaction of radicals with DNA,
oand these have been reviewed elsewhere [46, 82, 83].
However, reactions of carbenes, nitrenes, singlet oxy- o
(gen, strong nucleophiles, and photoexcited molecules
relevant to some DNA-damaging natural products have t
dbeen observed [83]. Common sites of DNA modification
by electrophilic natural products include G N7, A N3, A e
lN7, G C2-NH2, and occasionally G N3 (see Figure 1D).
Significant reaction selectivities among such nucleo- c
mphilic sites, occasionally via reversible reactions parti-
tioning to the thermodynamically most stable adducts, t
mare observed and often contribute to the apparent se-
quence selectivity [81]. Electrophilic modification of Pu t
cN7/N3 results in labilization of the glycosidic bond,
leading to depurination, formation of an abasic site, znd readily detectable strand scission. Alkylation at the
xocyclic nitrogens or carbonyl oxygens of the bases
r the phosphate oxygens affords stable adducts and
as not been observed, or at least detected, as fre-
uently. By contrast, H-atom abstraction from the de-
xyribose backbone represents the most prevalent rad-
cal-induced mode of natural product DNA damage and
lmost always leads to DNA cleavage. In contrast to
lkylation, this occurs without an inherent sequence or
ase selectivity, and the selectivity observed is typically
ntrinsic to the natural product-DNA interaction.
ore Complex Binding Modes
ot highlighted in the discussion above are natural pro-
ucts that bind or differentiate unique DNA structures
e.g., A, B, or Z-DNA, quadraplexes, bulges [6]), target
nd bind DNA-protein complexes more strongly than
NA itself (e.g., topoisomerases [12, 13]), or bind RNA
84], including the myriad of antibiotics that bind the
ucleic acid (RNA) embedded in ribosomes [85]. Each
f these areas constitutes an exciting direction for nat-
ral product nucleic acid recognition, for which lessons
nd generalizations are only now beginning to emerge.
mbedded Structural Features Contributing
o Biological Activity
eyond the fundamental aspects of sequence-selec-
ive DNA binding, there are many additional functional
eatures embedded in natural product structures that
ontribute to their properties.
echanisms of Activation
he concept of and many beautiful methods for in situ
ctivation have been discovered that protect and then
elease an embedded reactive species capable of DNA
lkylation or cleavage. Typically, these employ remark-
ble tactics that one could not imagine emerging from
e novo design efforts, fascinating reaction cascades
or release of the reactive species, and reveal rich and
nlightening chemistry that can be exploited on the
NA structure. Importantly, most such in situ activation
ethods have been discovered through investigations
f naturally occurring antitumor compounds that de-
ined their site and mechanism of action [86]. The pro-
ocative mechanisms of DNA modification continue to
rovide an endless source of inspiration for de novo
esign.
In addition to the subtle shape-dependent catalysis
f the duocarmycins, which does not entail a chemical
r enzymatic activation, cascades that enlist oxidation
e.g., bleomycin, aflatoxin, pyrrolizidine alkaloids), reduc-
ion (e.g., mitomycin and quinone-containing natural pro-
ucts, FR-66979, dynemicin), nucleophilic addition (e.g.,
nediynes, leinamycin, illudins), elimination (e.g., ptaqui-
oside), photochemical reactivity (e.g., porphyrins, furo-
oumarins), and metal chelation (e.g., bleomycin,
ithramycin) have been delineated. The classic reduc-
ive activation of the mitomycins [44, 87], the exquisite
etal chelation and O2 activation by bleomycin [43, 77],
he subtle conformational activation of CC-1065/duo-
armycins [48, 76], and the fascinating enediyne stabili-
ation and subsequent triggering mechanisms for Berg-
Review
1613man [88] or Myers [89] cyclization to reactive diradicals
attest to nature’s unparalleled creativity (Figure 5).
These have been reviewed elsewhere [86], but the hall-
mark of nature’s design is that the structural features
required for in situ or target-selective activation are
embedded in a structure that also possesses se-
quence-selective DNA binding properties. That is, the
necessary functional features are integrated into the
compact structure, not attached as a separate func-
tional domain.
Of the endogenous activations, only reductive activa-
tion has been linked to the selective cytotoxic action of
the molecules [86]. Similarly, of all the activation strate-
gies recognized, only photochemical activation has
been used exogenously to spatially define a site of
treatment accounting for selective activity [86]. For the
remainder, links between the activation method and se-
lective biological activity have not yet been made. It
may be that many natural products rely on other unre-
lated parameters for their selective action (e.g., selec-
tive cellular uptake).Figure 5. Nature’s Creativity in Natural Product Activation
From top to bottom: mitomycin (reductive activation), bleomycin
(metal chelation and O2 activation), duocarmycin (shape-depen-
dent catalysis), calicheamicin (Bergman cyclization), and neocarzi-
nostatin (Myers cyclization).Functional Activity and Selectivity
Although the understanding and structural depiction of
small molecule-DNA recognition by natural products has
advanced rapidly, the manner in which this translates into
selective biological activity rarely has been defined.
Rather, this productive activity was selected for in func-
tional screens that often also led to the natural product
identification. What is often defined with the examina-
tion of additional semisynthetic derivatives or synthetic
analogs is that the DNA binding properties (affinity, al-
kylation, crosslinking, and ss or ds cleavage) correlate
with biological activity, and this, along with suitable
functional assays, has been sufficient to advance many
drug discovery programs. The exceptional instances
where the origin of the selective activity was defined
have led to the validation of new therapeutic targets or
an even greater appreciation of the integrated func-
tional features of the natural product. The former is il-
lustrated nicely with the discoveries that camptothecin
and podophyllotoxin are potent topoisomerase I and II
inhibitors [30, 72, 73], respectively, trapping a cleavable
complex of the enzymes bound to DNA through forma-
tion of ternary DNA-enzyme-drug complexes, prevent-
ing religation following enzyme-mediated DNA cleav-
age and unwinding. This paved the way for rationale
drug-discovery programs, the clinical introduction of a
least ten semisynthetic derivatives, and validated two
important antineoplastic targets, which are the focus of
continued efforts today. The latter can be beautifully
illustrated with the mitomycins. Mitomycin C is unre-
active toward DNA at pH 7–8 [90] and has little inherent
DNA binding affinity or selectivity [91]. However, in situ
reduction of the quinone initiates an activation cascade
that proceeds initially through its semiquinone and hy-
droquinone, resulting in efficient DNA crosslinking. Un-
der aerobic conditions, the semiquinone and hydroqui-
none are reoxidized to the quinone by O2, preventing
its further entry into the activation cascade [92]. This
forms the basis for its selective toxicity and effective
use in the treatment of solid tumors that are character-
istically hypoxic (O2 deficient) [93, 94]. Thus, while cyto-
toxicity is a consequence of crosslinked DNA damage,
its biologically relevant selective cytotoxicity is pro-
vided by the in situ activation mechanism.
There are many other features of the natural products
that are integrated into their structures that make them
attractive which have not been discussed. Many have
multiple mechanisms of action that contribute to their
composite biological activity (e.g., anthracyclines) and
help alleviate the potential for acquired resistance. In
addition, having emerged from a biological milieu, they
often possess satisfactory ADME properties in spite of
their complex and often large structures.
The Unnatural Enantiomers
Advances in chemical synthesis have not only ac-
celerated increasingly detailed structure-activity studies
of the complex natural products, permitting deep-
seated structural changes needed to probe issues of
recognition or reactivity, but they have also allowed ac-
cess to their unnatural enantiomers. One of the most
provocative observations to emerge in the last decade
is that the unnatural enantiomers often possess DNA
Chemistry & Biology
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trable, or at least interesting, levels of biological activity.
Although the number of instances where this has been w
iexamined is still limited (Table 2), the observations are
remarkable and their full ramifications are yet to be ex- r
cploited. In the short term, the natural/unnatural enan-
tiomer comparisons have proven key to establishing
dthe fundamental features responsible for DNA binding
affinity and selectivity (see Figure 4) and, in some in- n
tstances, have provided effective, biologically active
compounds [48]. l
s
Nature’s Evolution versus Synthetic Optimization
One of the most misguided generalizations associated C
with this field and natural products in general is that
they must constitute optimal structures, since they N
iemerged from nature’s evolutionary selection. The flaw
in this rationalization is that nature rarely selected the f
fcandidates on the same basis for which we find them
useful. Thus, there is no reason to expect natural pro- i
tduct leads to constitute an optimized candidate. This
is illustrated nicely with the two extreme examples of f
sbleomycin and isochrysohermidin. There is little doubt
that bleomycin evolved in bacteria as a potent, cata- e
tlytic, ds DNA (or RNA) cleaving molecule to induce cell
death selectively against invasive organisms, since (
tnearly each feature, substituent, and functional group
in this molecule contributes to this function [43, 77]. d
tNonetheless, its useful qualities as an antitumor drug
are derived in part from both its selective cellular up- t
qtake and atypical metabolic deactivation (lack of bleo-
mycin hydrolase) in sensitive tumor cell lines [104], fea- a
itures that were selected through screening and are
unlikely to be optimal. In contrast to bleomycin, the h
gpresence of isochrysohermidin in Mercurialis perennis
has nothing to do with its DNA binding properties (re- dTable 2. DNA Binding Selectivity and Biological Activity of the Natural and Unnatural Enantiomers of Selected Natural Products
Natural Enantiomer Selectivity Activity Unnatural Enantiomer Selectivity Activity Reference
(+)-CC-1065 5#-WWWWA 20 pM (IC50, L1210) ent-(−)-CC-1065 5#-WAWWW 20 pM (IC50, L1210) [48]
(+)-Duocarmycin SA 5#-WWWA 6–10 pM (IC50, L1210) ent-(−)-duocarmycin SA 5#-WAWW 100 pM (IC50, L1210) [48, 95]
(+)-Duocarmycin A 5#-WWWA 200 pM (IC50, L1210) ent-(−)-duocarmycin A 5#-WAWW >20 nM (IC50, L1210) [48, 96]
(+)-Yatakemycin 5#-WWAWW 5 pM (IC50, L1210) ent-(−)-yatakemycin 5#-WWAWW 5 pM (IC50, L1210) [50, 108]
Fredericamycin A ND 0.03 g/ml (IC50, L1210) ent-fredericamycin A ND 0.04 g/ml (IC50, [97]
L1210)
Mitomycin C 5#-CG 0.06 M (IC50, HeLa SA) ent-mitomycin C 5#-CG 0.11 M (IC50, [98]
crosslinks crosslinks HeLa SA)
(+)-Roseophilin ND 0.2 M (IC50, L1210) ent-(−)-roseophilin ND 0.1 M (IC50, L1210) [99]
(+)-Daunorubicin B-DNA 0.4 M (KB3.1 ent-(−)-daunorubicin Z-DNA 8.3 M (KB3.1 [100]
sensitive), >100 M sensitive), 19 nM
(KB-VI MDR) (KB-VI MDR)
Bleomycin B2 binds both D- [101]
and L-DNA
but cleaves
only natural
D-DNA
(+)-Camptothecin ND 0.04 M (IC50, KB), (−)-camptothecin ND 0.4 M (IC50, KB), [102, 103]
0.03 M (IC50, SPS), 2 M (IC50, SPS),
52% inhibition of 20% inhibition of
topo I at 10 M topo I at 10 M
ND, not determined.ersible crosslinking [58]). It is the oxidative degrada-
ion product of a purple pigment found in the flower,
hich, through screening, was found to possess the
nteresting DNA binding properties [58]. There is no
eason to suspect that its DNA crosslinking and biologi-
al properties have somehow been optimized.
Rather, the challenge is to fully understand the subtle
esign elements that nature provided in the form of a
atural product and work to extend the solution
hrough rational design elements to provide more se-
ective, potent, or efficacious compounds designed
pecifically for the problems under study.
onclusions
ucleic acids occupy a position of central importance
n biological systems. It is the site at which genetic in-
ormation is stored, accessed, and replicated in the
orm of a linear nucleotide code. DNA is transcribed
nto RNA, which is ultimately translated into proteins
hat provide much of the structure and carry out the
unction of life itself. Today, most therapeutics act by
electively targeting proteins, often the products of ab-
rrant gene expression. However, it is reasonable to an-
icipate a time when therapeutics target the source
DNA) as well as the product (protein) of aberrant gene
ranscription. Fundamental to such opportunities is a
etailed understanding of gene expression [105] and
he development of small molecules that can selec-
ively modulate it. Imaginative paradigms for the se-
uence-selective targeting and modification of nucleic
cids by small molecules and some of the first insights
nto their modulation of aberrant gene transcription
ave emerged largely from the examination of biolo-
ically active natural products. In the short term, the
iscovery of biologically active DNA binding natural
Review
1615products has and will continue to provide a rich source
of new therapeutics (anticancer, antiviral, antibiotic); re-
veal new mechanisms of achieving cellular selectivity;
define unprecedented DNA recognition motifs and
chemical reactions; reveal unforeseen biological path-
ways and validate new therapeutic targets; reveal new
mechanisms of in situ chemical or enzymatic activa-
tion; inspire new experimental tools (e.g., footprinting
and affinity cleavage); and serve as prototypes for de-
sign of therapeutics embodying compact structures of
integrated function.
For those who might suspect that the important DNA
binding features of such molecules have long ago been
discovered, it is important to note that the 2:1 binding
of distamycin was only revealed in 1989 [75], the key
minor groove triplex H bonding of bleomycin responsi-
ble for the sequence-selective cleavage was first dis-
closed in 1996 [106], and the source of the catalysis
for the duocarmycin DNA alkylation reaction was first
recognized in 1997 [107], despite their 20–40 year
period of investigation. Undoubtedly, there are many
more lessons yet to be learned from the existing natural
products and new paradigms yet to be revealed by as
yet undiscovered natural products.
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